Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

289 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials.
Rassy E, Filleron T, Viansone A, Lacroix-Triki M, Rivera S, Desmoulins I, Serin D, Canon JL, Campone M, Gonçalves A, Levy C, Cottu P, Petit T, Eymard JC, Debled M, Bachelot T, Dalenc F, Roca L, Lemonnier J, Delaloge S, Pistilli B. Rassy E, et al. Among authors: cottu p. Breast Cancer Res Treat. 2023 Jun;199(2):371-379. doi: 10.1007/s10549-023-06912-4. Epub 2023 Mar 29. Breast Cancer Res Treat. 2023. PMID: 36988749
Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts.
Cottu P, Marangoni E, Assayag F, de Cremoux P, Vincent-Salomon A, Guyader Ch, de Plater L, Elbaz C, Karboul N, Fontaine JJ, Chateau-Joubert S, Boudou-Rouquette P, Alran S, Dangles-Marie V, Gentien D, Poupon MF, Decaudin D. Cottu P, et al. Breast Cancer Res Treat. 2012 Jun;133(2):595-606. doi: 10.1007/s10549-011-1815-5. Epub 2011 Oct 16. Breast Cancer Res Treat. 2012. PMID: 22002565
Treatment patterns, clinical outcomes and health care costs associated with HER2-positive breast cancer with central nervous system metastases: a French multicentre observational study.
Baffert S, Cottu P, Kirova YM, Mercier F, Simondi C, Bachelot T, Le Rhun E, Levy C, Gutierrez M, Madranges N, Moldovan C, Coudert B, Spaëth D, Serin D, Cotté FE, Benjamin L, Maillard C, Laulhere-Vigneau S, Durand-Zaleski I. Baffert S, et al. Among authors: cottu p. BMC Health Serv Res. 2013 Oct 31;13:456. doi: 10.1186/1472-6963-13-456. BMC Health Serv Res. 2013. PMID: 24176086 Free PMC article.
Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer.
Pernin V, Belin L, Cottu P, Bontemps P, Lemanski C, De La Lande B, Baumann P, Missohou F, Levy C, Peignaux K, Reynaud-Bougnoux A, Denis F, Gobillion A, Bollet M, Vago NA, Dendale R, Campana F, Fourquet A, Kirova YM. Pernin V, et al. Among authors: cottu p. Br J Radiol. 2015 Apr;88(1048):20140800. doi: 10.1259/bjr.20140800. Epub 2015 Feb 3. Br J Radiol. 2015. PMID: 25645108 Free PMC article. Clinical Trial.
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).
Bonnefoi H, Grellety T, Tredan O, Saghatchian M, Dalenc F, Mailliez A, L'Haridon T, Cottu P, Abadie-Lacourtoisie S, You B, Mousseau M, Dauba J, Del Piano F, Desmoulins I, Coussy F, Madranges N, Grenier J, Bidard FC, Proudhon C, MacGrogan G, Orsini C, Pulido M, Gonçalves A. Bonnefoi H, et al. Among authors: cottu p. Ann Oncol. 2016 May;27(5):812-8. doi: 10.1093/annonc/mdw067. Epub 2016 Feb 18. Ann Oncol. 2016. PMID: 27052658 Free article. Clinical Trial.
289 results